Interferon-β efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 1030-1034

  Xiao, H B ^a   Zhou, W Y ^b   Chen, X F ^b   Mei, J ^a   Lv, Z W ^b   Ding, F B ^a   Li, G Q ^a   Zhong, H ^a   Bao, C R ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

EPCs; IFN ; VEGF

Indexed keywords

BETA INTERFERON; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMBRYO; ENDOTHELIAL PROGENITOR CELL; EX VIVO GENE TRANSFER; EX VIVO STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-BETA; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84867405622     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.171     Document Type: Article

References (11)

1. Sreeramoju P, Libutti SK. Strategies for targeting tumors and tumor vasculature for cancer therapy. Adv Genet 2010; 69: 135 -152.
2. Horsman MR, Bohn AB, Busk M. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Exp Oncol 2010; 32: 143-148.
3. Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005; 12: 994-1005. (Pubitemid 41723033)
4. Le Ricousse-Roussanne S, Barateau V, Contreres JO, Boval B, Kraus-Berthier L, Tobelem G. Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature. Cardiovasc Res 2004; 62: 176-184. (Pubitemid 38326823)
5. Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K, Otte M et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112. (Pubitemid 30321161)
6. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427. (Pubitemid 30183318)
7. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H etal. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularization. J Clin Invest 2000; 105: 1527-1536. (Pubitemid 30390303)
8. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964-3972. (Pubitemid 29335849)
9. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147. (Pubitemid 38524883)
10. Park HE, Baek SH, Min J, Chang YT, Kang DK, Chang SI et al. Myoseverin is a potential angiogenesis inhibitor by inhibiting endothelial cell function and endothelial progenitor cell differentiation. DNA Cell Biol 2006; 25: 514-522. (Pubitemid 44763220)
11. Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.